Transient Sox9 Expression Facilitates Progression to Castrate Resistant Prostate Cancer.

CONCLUSIONS: Developmentally reprogrammed PCa cell models recapitulate features of clinically-advanced prostate tumors including downregulated Rb1/p53 and overexpression of Sox2 with Sox9. Sox9 is a marker of a transitional state that identifies PCa cells under the stress of therapeutic assault and facilitates progression to therapy resistance. Its expression may index the relative activity of the NF-κB pathway.
PMID: 31919137 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - January 8, 2020 Category: Cancer & Oncology Authors: Nouri M, Massah S, Caradec J, Lubik AA, Li N, Truong S, Lee AR, Fazli L, Ramnarine VR, Lovnicki JM, Moore J, Wang M, Foo J, Gleave ME, Hollier BG, Nelson CC, Dong X, Collins CC, Buttyan R Tags: Clin Cancer Res Source Type: research